The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer
Abstract
BACKGROUND: Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and enzalutamide monotherapy, as compared with androgen-deprivation therapy alone, are unknown. METHODS: In this phase 3 trial, we enrolled patients with prostate cancer who had high-risk biochemical recurrence with a prostate-specific antigen doubling time of 9 months or less. Patients were randomly assigned, in a 1:1:1 ratio, to receive enzalutamide (160 mg) daily plus leuprolide every 12 weeks (combination group), placebo plus leuprolide (leuprolide-alone group), or enzalutamide monotherapy (monotherapy group). The primary end point was metastasis-free survival, as assessed by blinded independent central review, in the combination group as compared with the leuprolide-alone group. A key secondary end point was metastasis-free survival in the monotherapy group as compared with the leuprolide-alone group. Other secondary end points were patient-reported outcomes and safety. RESULTS: A total of 1068 patients underwent randomization: 355 were assigned to the combination group, 358 to the leuprolide-alone group, and 355 to the monotherapy group. The patients were followed for a median of 60.7 months. At 5 years, metastasis-free survival was 87.3% (95% confidence interval [CI], 83.0 to 90.6) in the combination group, 71.4% (95% CI, 65.7 to 76.3) in the leuprolide-alone group, and 80.0% (95% CI, 75.0 to 84.1) in the monotherapy group. With respect to metastasis-free survival, enzalutamide plus leuprolide was superior to leuprolide alone (hazard ratio for metastasis or death, 0.42; 95% CI, 0.30 to 0.61; P<0.001); enzalutamide monotherapy was also superior to leuprolide alone (hazard ratio for metastasis or death, 0.63; 95% CI, 0.46 to 0.87; P = 0.005). No new safety signals were observed, with no substantial between-group differences in quality-of-life measures. CONCLUSIONS: In patients with prostate cancer with high-risk biochemical recurrence, enzalutamide plus leuprolide was superior to leuprolide alone with respect to metastasis-free survival; enzalutamide monotherapy was also superior to leuprolide alone. The safety profile of enzalutamide was consistent with that shown in previous clinical studies, with no apparent detrimental effect on quality of life. (Funded by Pfizer and Astellas Pharma; EMBARK ClinicalTrials.gov number, NCT02319837.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,071
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903307 · Cited by 1,564
Freedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2005) · JAMA · doi:10.1001/jama.294.4.433 · Cited by 1,358
Self-citationArmstrong, A. J., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Azad, A., Alcaraz, A., Alekseev, B., Iguchi, T., Shore, N. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00799 · Cited by 1,217
Self-citationEnzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Hussain, M., Fizazi, K., Saad, F., Rathenborg, P., Shore, N., Ferreira, U., Ivashchenko, P., Demirhan, E., Modelska, K., Phung, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800536 · Cited by 1,035
Self-citationFizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriguez-Antolin, A., Alekseev, B. Y., Özgüroğlu, M., Ye, D., Feyerabend, S., Protheroe, A., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30082-8 · Cited by 833
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
Xie, W., Regan, M. M., Buyse, M., Halabi, S., Kantoff, P. W., Sartor, O., Soule, H., Clarke, N. W., Collette, L., Dignam, J. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9987 · Cited by 433
Attard, G., Murphy, L., Clarke, N. W., Cross, W., Jones, R. J., Parker, C. C., Gillessen, S., Cook, A., Brawley, C., Amos, C. L., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02437-5 · Cited by 386
GLEAVE, M. E., GOLDENBERG, S. L., CHIN, J. L., WARNER, J., SAAD, F., KLOTZ, L. H., JEWETT, M., KASSABIAN, V., CHETNER, M., DUPONT, C., et al. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65971-x · Cited by 326
Self-citationImproved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Armstrong, A. J., Azad, A. A., Iguchi, T., Szmulewitz, R. Z., Petrylak, D. P., Holzbeierlein, J., Villers, A., Alcaraz, A., Alekseev, B., Shore, N. D., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00193 · Cited by 316
Self-citationAttard, G., Murphy, L. R., Clarke, N. W., Cross, W. R., Jones, R. J., Parker, C. C., Gillessen, S., Cook, A. D., Brawley, C., Amos, C. L., et al. (2022) · BORIS (University Library Bern) · doi:10.48350/164184 · Cited by 303
Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report
Larry Goldenberg, S., Bruchovsky, N., Gleave, M. E., Sullivan, L. D., & Akakura, K. (1995) · Urology · doi:10.1016/s0090-4295(99)80092-2 · Cited by 284
Self-citationSpratt, D. E., Yousefi, K., Deheshi, S., Ross, A. E., Den, R. B., Schaeffer, E. M., Trock, B. J., Zhang, J., Glass, A. G., Dicker, A. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.2811 · Cited by 247
Self-citationFreedland, S. J., Humphreys, E. B., Mangold, L. A., Eisenberger, M., Dorey, F. J., Walsh, P. C., & Partin, A. W. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.0572 · Cited by 216
Self-citationGleave, M. E., Goldenberg, S. L., Jones, E. C., et al. (1996) · The Journal of Urology · doi:10.1016/s0022-5347(01)66598-4 · Cited by 160
Self-citationKupelian, P. A., Mahadevan, A., Reddy, C. A., Reuther, A. M., & Klein, E. A. (2006) · Urology · doi:10.1016/j.urology.2006.03.075 · Cited by 141
Chowdhury, S., Bjartell, A., Lumen, N., Maroto, P., Paiss, T., Gomez-Veiga, F., Birtle, A., Kramer, G., Kalinka, E., Spaëth, D., et al. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00720-2 · Cited by 86
Metastasis-free Survival — A New End Point in Prostate Cancer Trials
Beaver, J. A., Kluetz, P. G., & Pazdur, R. (2018) · New England Journal of Medicine · doi:10.1056/nejmp1805966 · Cited by 78
Shore, N. D., Antonarakis, E. S., Cookson, M. S., Crawford, E. D., Morgans, A. K., Albala, D. M., Hafron, J. M., Harris, R. G., Saltzstein, D. R., Brown, G. A., et al. (2020) · The Prostate · doi:10.1002/pros.23967 · Cited by 67
Self-citationShore, N. D., Renzulli, J., Fleshner, N. E., Hollowell, C. M. P., Vourganti, S., Silberstein, J. L., Siddiqui, R., Hairston, J., Elsouda, D., Russell, D., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.1641 · Cited by 62
Self-citationInterval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death
D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, M. J., & Kantoff, P. W. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.082 · Cited by 49
TOMBAL, B. F., Borre, M., Rathenborg, P., Werbrouck, P., Poppel, H. V., Heidenreich, A., Iversen, P., Braeckman, J., Heráček, J., Baskin-Bey, E. S., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.027 · Cited by 48
Fred Saad, C., Small, E. J., Feng, F. Y.-C., Graff, J. N., Olmos, D., Hadaschik, B. A., Oudard, S. M., Londhe, A., Bhaumik, A., Gitlitz, A. M. L., et al. (2021) · European Urology · doi:10.1016/j.eururo.2021.11.020 · Cited by 48
Markowski, M. C., Chen, Y., Feng, Z., Cullen, J. C., Trock, B. J., Suzman, D. L., Antonarakis, E. S., Paller, C. J., Rosner, I. L., Han, M., et al. (2019) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.08.002 · Cited by 45
Armstrong, A. J., Lin, P., Higano, C. S., Iversen, P., Sternberg, C. N., TOMBAL, B. F., Phung, D., Parli, T., Krivoshik, A., & Beer, T. M. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.11.005 · Cited by 41
Armstrong, A. J., Fred Saad, C., Phung, D., Dmuchowski, C., Shore, N. D., Fizazi, K. S., Hirmand, M., Forer, D., Scher, H. I., & Bono, J. S. D. (2017) · Cancer · doi:10.1002/cncr.30587 · Cited by 40
Self-citationGeorge, D. J., Ramaswamy, K., Huang, A., Russell, D., Mardekian, J., Schultz, N. M., Janjan, N. A., & Freedland, S. J. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00463-9 · Cited by 37
Self-citationFreedland, S. J., Giorgi, U. D., Gleave, M. E., Rosbrook, B., Shen, Q., Sugg, J. E., Haas, G. P., & Shore, N. D. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-046588 · Cited by 36
Self-citationEnzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer
Freedland, S. J., Gleave, M. E., Giorgi, U. D., Rannikko, A. S., Pieczonka, C. M., Tutrone, R. F., Jr., Venugopal, B., Woo, H. H., Backhaus, M., Supiot, S., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300251 · Cited by 34
Self-citationTombal, B., Borre, M., Rathenborg, P., Werbrouck, P., Van Poppel, H., Heidenreich, A., Iversen, P., Braeckman, J., Heracek, J., Baron, B., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2017.08.103 · Cited by 26
Hussain, M., Sternberg, C. N., Efstathiou, E., Fizazi, K. S., Shen, Q., Lin, X., Sugg, J. E., Steinberg, J., Nørby, B., Giorgi, U. D., et al. (2023) · The Journal of Urology · doi:10.1097/ju.0000000000003084 · Cited by 20
Self-citationA drug safety evaluation of enzalutamide to treat advanced prostate cancer
Fred Saad, C., Hamilou, Z., & Lattouf, J. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1919620 · Cited by 10
Freedland, S. J., Hong, A., El-Chaar, N. N., Murty, S., Ramaswamy, K., Coutinho, A. D., Nimke, D., & Morgans, A. K. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00622-6 · Cited by 7
Self-citationTOMBAL, B. F., Borre, M., Rathenborg, P., Werbrouck, P., Poppel, H. V., Heidenreich, A., Iversen, P., Braeckman, J., Heráček, J., Baskin-Bey, E. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.4_suppl.62 · Cited by 5
Cited by
Raychaudhuri, R., Lin, D. W., & Montgomery, R. B. (2025) · JAMA · doi:10.1001/jama.2025.0228 · Cited by 355
Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., De Santis, M., Farolfi, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.04.010 · Cited by 352
Prostate Cancer, Version 3.2024: Featured Updates to the NCCN Guidelines
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Bitting, R., Chapin, B., Cheng, H. H., D’Amico, A. V., Desai, N., Dorff, T., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0019 · Cited by 312
Metadata
- Authors
- Freedland, S. J., de Almeida Luz, M., De Giorgi, U., Gleave, M., Gotto, G. T., Pieczonka, C. M., Haas, G. P., Kim, C.-S., Ramirez-Backhaus, M., Rannikko, A., Tarazi, J., Sridharan, S., Sugg, J., Tang, Y., Tutrone, R. F., Venugopal, B., Villers, A., Woo, H. H., Zohren, F., & Shore, N. D.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-10-19
- Volume
- 389
- Issue
- 16
- Pages
- 1453-1465
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387735431
- Cited by
- 319
- References
- 35
- FWCI
- 50.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.